Stay updated on Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, signaling a minor update to the page's version rather than a substantive change to its content.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page footer now shows an updated release/revision version (from v3.5.2 to v3.5.3) for the ClinicalTrials.gov interface.SummaryDifference0.0%

- Check30 days agoChange DetectedRevision: v3.5.2 is now shown on the page, replacing the previous Revision: v3.5.0.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.0%

- Check66 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3; no study details or navigation were affected.SummaryDifference0.0%

- Check95 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-lapse notice (and its prior Revision: v3.4.1). No core study content, eligibility criteria, or results were modified.SummaryDifference0.3%

Stay in the know with updates to Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial page.